Henrike Knacke1, Maik Pietzner1, Kieu Trinh Do1, Werner Römisch-Margl1, Gabi Kastenmüller1, Uwe Völker1, Henry Völzke1, Jan Krumsiek1, Anna Artati1, Henri Wallaschofski1, Matthias Nauck1, Karsten Suhre1, Jerzy Adamski1, Nele Friedrich1. 1. Institute of Clinical Chemistry and Laboratory Medicine (H.K., M.P., H.W., M.N., N.F.) and Institute for Community Medicine (H.V.), University Medicine Greifswald, Interfaculty Institute for Genetics and Functional Genomics (U.V.), University Medicine and Ernst-Moritz Arndt-University Greifswald, and German Center for Cardiovascular Research (M.N., N.F.), partner site Greifswald, 17475 Greifswald, Germany; Institute of Computational Biology (K.T.D., J.K., K.S.), Helmholtz-Zentrum München, and German Center for Diabetes Research (J.K.), and Institute of Bioinformatics and Systems Biology (W.R.-M., G.K.), Helmholtz Zentrum München, German Research Center for Environmental Health, and Institute of Experimental Genetics (A.A., J.A.), Genome Analysis Center, Helmholtz Zentrum München, Neuherberg, Germany, and German Center for Diabetes Research (J.A.), 85764 München-Neuherberg, Germany; Schwerpunktpraxis für Diabetes und Hormonerkrankungen (H.W.), 99094 Erfurt, Germany; Weill Cornell Medical College in Qatar (K.S.), Education City, Qatar Foundation, Doha, Qatar; Lehrstuhl für Experimentelle Genetik (J.A.), Technische Universität München, 85350 Freising-Weihenstephan, Germany; Research Centre for Prevention and Health (N.F.), Capital Region of Denmark, 2600 Glostrup, Denmark.
Abstract
OBJECTIVE: IGF-1 is known for its various physiological and severe pathophysiological effects on human metabolism; however, underlying molecular mechanisms still remain unsolved. To reveal possible molecular mechanisms mediating these effects, for the first time, we associated serum IGF-1 levels with multifluid untargeted metabolomics data. METHODS: Plasma/urine samples of 995 nondiabetic participants of the Study of Health in Pomerania were characterized by mass spectrometry. Sex-specific linear regression analyses were performed to assess the association of IGF-1 and IGF-1/IGF binding protein 3 ratio with metabolites. Additionally, the predictive ability of the plasma and urine metabolome for IGF-1 was assessed by orthogonal partial least squares analyses. RESULTS AND CONCLUSIONS: We revealed a multifaceted image of associated metabolites with large sex differences. Confirming previous reports, we detected relations between IGF-1 and steroid hormones or related intermediates. Furthermore, various associated metabolites were previously mentioned regarding IGF-1-associated diseases, eg, betaine and cortisol in cardiovascular disease and metabolic syndrome, lipid disorders, and diabetes, or have previously been found to associate with differentiation and proliferation or mitochondrial functionality, eg, phospholipids. bradykinin, fatty acid derivatives, and cortisol, which were inversely associated with IGF-1, might establish a link of IGF-1 with inflammation. For the first time, we showed an association between IGF-1 and pipecolate, a metabolite linked to amino acid metabolism. Our study demonstrates that IGF-1 action on metabolism is tractable, even in healthy subjects, and that the findings provide a solid basis for further experimental/clinical investigation, eg, searching for inflammatory or cardiovascular disease- or metabolic syndrome-associated biomarkers and therapeutic targets.
OBJECTIVE:IGF-1 is known for its various physiological and severe pathophysiological effects on human metabolism; however, underlying molecular mechanisms still remain unsolved. To reveal possible molecular mechanisms mediating these effects, for the first time, we associated serum IGF-1 levels with multifluid untargeted metabolomics data. METHODS: Plasma/urine samples of 995 nondiabetic participants of the Study of Health in Pomerania were characterized by mass spectrometry. Sex-specific linear regression analyses were performed to assess the association of IGF-1 and IGF-1/IGF binding protein 3 ratio with metabolites. Additionally, the predictive ability of the plasma and urine metabolome for IGF-1 was assessed by orthogonal partial least squares analyses. RESULTS AND CONCLUSIONS: We revealed a multifaceted image of associated metabolites with large sex differences. Confirming previous reports, we detected relations between IGF-1 and steroid hormones or related intermediates. Furthermore, various associated metabolites were previously mentioned regarding IGF-1-associated diseases, eg, betaine and cortisol in cardiovascular disease and metabolic syndrome, lipid disorders, and diabetes, or have previously been found to associate with differentiation and proliferation or mitochondrial functionality, eg, phospholipids. bradykinin, fatty acid derivatives, and cortisol, which were inversely associated with IGF-1, might establish a link of IGF-1 with inflammation. For the first time, we showed an association between IGF-1 and pipecolate, a metabolite linked to amino acid metabolism. Our study demonstrates that IGF-1 action on metabolism is tractable, even in healthy subjects, and that the findings provide a solid basis for further experimental/clinical investigation, eg, searching for inflammatory or cardiovascular disease- or metabolic syndrome-associated biomarkers and therapeutic targets.
Authors: Nobuto Kaneko; Meredith L Journey; Chrys M Neville; Marc Trudel; Brian R Beckman; Munetaka Shimizu Journal: Fish Physiol Biochem Date: 2019-07-11 Impact factor: 2.794
Authors: Man Li; Nisa M Maruthur; Stephanie J Loomis; Maik Pietzner; Kari E North; Hao Mei; Alanna C Morrison; Nele Friedrich; James S Pankow; Matthias Nauck; Eric Boerwinkle; Alexander Teumer; Elizabeth Selvin; Anna Köttgen Journal: Sci Rep Date: 2017-06-06 Impact factor: 4.379
Authors: Annette Masuch; Maik Pietzner; Martin Bahls; Kathrin Budde; Gabi Kastenmüller; Stephanie Zylla; Anna Artati; Jerzy Adamski; Henry Völzke; Marcus Dörr; Stephan B Felix; Matthias Nauck; Nele Friedrich Journal: Cardiovasc Diabetol Date: 2018-08-28 Impact factor: 9.951
Authors: Betina Biagetti; J R Herance; Roser Ferrer; Anna Aulinas; Martina Palomino-Schätzlein; Jordi Mesa; J P Castaño; Raul M Luque; Rafael Simó Journal: J Clin Med Date: 2019-09-26 Impact factor: 4.241